Regulatory expansion positions deucravacitinib 6 mg once daily as a first-in-class oral TYK2 option for active PsA, complementing its prior plaque psoriasis indication. POETYK PsA-1 showed significant ...
The FDA has approved deucravacitinib for adults with active psoriatic arthritis, according to a press release from Bristol ...
Clinical utility may be greatest with careful patient selection, given frailty-associated toxicity and potential endpoint inflation in indolent tumors, warranting larger validation cohorts and ...
Ipsen receives CHMP’s positive opinion on Ojemda for treating monotherapy of children with relapsed or refractory BRAF-altered paediatric low-grade glioma: Paris Wednesday, Marc ...
The FDA granted full approval encorafenib (Braftovi) in combination with cetuximab (Erbitux) and fluorouracil-based ...
Researchers found that combining trametinib, rigosertib, and a CD40 agonist blocked immune-suppressive B cells and restored ...
For patients with advanced melanoma without BRAF mutation who no longer respond to immune checkpoint inhibitors, treatment ...
If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with ...
Morning Overview on MSN
How gene mutations disrupt cell growth and trigger cancer?
Cancer begins when mutations in specific genes override the body’s built-in controls on cell division, allowing rogue cells ...
Shifting the focus from organ to biomarker has unlocked new options for rare and advanced cancers. Uneven efficacy, diagnostic access, and regulation still slow clinical rollout.
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales ...
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results